Advertisement

FDA grants emergency use authorization to COVID-19 Breathalyzer test

The FDA on Thursday granted emergency use authorization to the InspectIR COVID-19 Breathalyzer, pictured here, which separates and identifies chemical compounds in breath associated with the virus. Screencapture/InspectIR Systems/YouTube
The FDA on Thursday granted emergency use authorization to the InspectIR COVID-19 Breathalyzer, pictured here, which separates and identifies chemical compounds in breath associated with the virus. Screencapture/InspectIR Systems/YouTube

April 14 (UPI) -- The U.S. Food and Drug Administration on Thursday granted emergency use authorization to the first COVID-19 test to use breath samples.

The FDA approved the InspectIR COVID-19 Breathalyzer for use in medical facilities and mobile testing sites.

Advertisement

The device, which is about the size of a piece of carry-on luggage, uses a technique called gas chromatography gas mass-spectrometry to separate and identify chemical compounds associated with COVID-19 infections.

According to the FDA, InspectIR can produce 100 instruments per week to evaluate about 160 samples per day, providing results in less than 3 minutes.

In a study, the InspectIR Breathalyzer accurately identified 91.2% of positive tests and 99.3% of negative tests.

The FDA said that a positive test should be confirmed with a molecular PCR test.

"Today's authorization is yet another example of the rapid innovation occurring with diagnostic tests for COVID-19," said Jeff Shuren, director of the FDA's, Center for Devices and Radiological Health. "The FDA continues to support the development of novel COVID-19 tests with the goal of advancing technologies that can help address the current pandemic and better position the U.S. for the next public health emergency."

Advertisement

Latest Headlines

Advertisement
Advertisement

Follow Us

Advertisement